对于耐火性头癌的多剂化学疗法
I-Wei Ho1,2,3,4, Tien-Hua Chen1,4, Peter Mu-Hsin Chang1,5
1Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Journal of the Chinese Medical Association : JCMA
|January 8, 2026
概括
MEMOCLUB化疗方案显示出作为白金耐火性头癌的救援疗法的承诺. 添加 cetuximab 显著改善了存活率,特别是在以前没有接受 cetuximab 的患者中.
科学领域:
- 在瘤学瘤学.
- 头部和部癌症研究研究
- 化疗疗方案 化疗方案
背景情况:
- 复发或转移的头支状细胞癌 (R/M HNSCC) 的预后不好.
- 免疫疗法只对一小部分患者 (高PD-L1表达) 有好处.
- 对于耐火或低PD-L1 HNSCC患者,存在有限的选择.
研究的目的:
- 评估MEMOCLUB治疗方案对耐火R/M HNSCC的疗效和安全性.
- 评估将 cetuximab 添加到 MEMOCLUB 治疗方案的影响.
- 在这个患者群体中确定生存的预后因素.
主要方法:
- 对124名白金耐火R/M HNSCC患者进行了回顾性队列研究.
- 与 cetuximab 或没有 cetuximab (2015-2022) 一起使用的 MEMOCLUB 疗法 (2015-2022).
- 通过客观反应率 (ORR),无进展生存率 (PFS) 和整体生存率 (OS) 衡量有效性.
主要成果:
- 中位数PFS:2.9个月;中位数OS:5.3个月.
- ORR: 10.5%; 疾病控制率: 27.4%. 疾病控制率: 10.5%; 疾病控制率: 27.4%
- 同时服用 cetuximab 显著改善了 OS,特别是在未服用 cetuximab 的患者中. 贫血是最常见的不良事件.
结论:
- MEMOCLUB是一种可行的救援疗法,用于耐火性HNSCC,具有可接受的耐受性.
- 塞图西马布的补充显著有利于以前没有服用塞图西马布的患者,改善了生存结果.
- 同时服用 cetuximab 对这个子组来说是一个潜在的有利的策略.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
564
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
564
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
801
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
801
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
594
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
594
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K


